Immatics is a leading cancer immunotherapy company and the global leader in the discovery of novel targets for various types of cancer immunotherapies. Our products work by specifically activating and redirecting a patient’s immune system to recognize and kill cancer cells through the recognition of our novel and proprietary targets.